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Introduction
Deep venous thrombosis (DVT) in the lower extremities is the most frequent manifestation of venous thromboembolism (VTE), with an incidence of 0.48 to 1.6 cases/1000 persons-year among community residents [1] [2] [3] . It is a common condition affecting mainly inpatients and rates increase with age. The most lifethreatening manifestation is pulmonary embolism (PE), affecting 0.23 to 0.69 cases/1000 person-years [4] . The treatment of VTE recommended by the American College of Chest Physicians [5] involves short-term low-molecular-weight-heparin (LMWH) or unfractionated heparin (UFH) therapy plus long-term oral warfarin therapy. Anticoagulant therapy with UFH followed by warfarin prevents thrombus extension, reduces the risk of recurrent thrombosis, and prevents death in patients with VTE [6, 7] . Subcutaneous LMWH is as effective and safe as conventional UFH therapy, but does not require laboratory monitoring and is less likely to cause bleeding, immune thrombocytopenia, and osteoporosis [8 -10] . LMWH preparartions differ considerably in composition, which could result in different antithrombotic effects, but there is no evidence that any LMWH preparation is better or worse than another in terms of efficacy or safety outcomes [11] .
Enoxaparin is among the most widely studied treatments for VTE [12, 13] . Despite LMWH having a greater acquisition cost, previous pharmacoeconomic analyses have shown that LMWH is more cost-effective than UFH [14 -16] . It has been calculated that outpatient treatment with LMWH may save $1641 per patient in comparison to UFH hospital treatment [17] . This economic benefit of outpatient treatment of VTE seems to be present in different health systems of developed countries, although the same can not be extrapolated to developing nations. Economic evaluations in developing countries are desirable to estimate VTE hospital treatment cost with UFH and LMWH, because people with low income do not have access to outpatient treatment with LMWH. We conducted a cohort study to evaluate the direct costs of short-term heparin anticoagulation treatment for VTE in a large teaching hospital located in southern Brazil, from the institutional perspective.
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Methods
This was a cohort study that prospectively included patients hospitalized from March 2005 through January 2007 in a university-affiliated, general tertiary teaching hospital with 749 beds in southern Brazil. These patients had been treated with intravenous UFH or subcutaneous LWMH for suspected or confirmed DVT or PE. The study was approved by the institutional review board.
Patients receiving UFH or LWMH were identified through the institution's computerized prescription system and had their clinical records revised to be included in the study. All patients receiving an anticoagulation dose of heparin to treat VTE were potentially eligible. The LMWH included on the hospital formulary was enoxaparin, based in the lowest price acquisition policy of the institution. Patients identified with DVT or PE were prospectively followed-up until the end of the heparin anticoagulation period. The only exclusion criterion was age younger than 18 years. Data about diagnosis confirmation, anticoagulation regimen, duration of treatment, laboratory monitoring with activated partial thromboplastin time (aPTT), bleeding, thrombocytopenia, blood transfusion, and protamine prescription were recorded for all included patients. Adverse events potentially related to DVT or its treatment were defined as combined endpoint and included in-hospital death, bleeding, or recurrent VTE.
Costs were assessed directly from the hospital's records on prices paid for each one of the elements involved in patients' assistance, considering the prices during their period of hospitalization. This information was provided directly by the hospital, so retrospective costs did not have to be estimated based on any other indirect information. Total medication costs were calculated for each patient, considering the prospectively collected data on medicines, supplies, and laboratory tests. To estimate direct medical costs we computed the acquisition costs of drugs and supplies associated with UFH treatment, laboratory tests, and hospitalization cost according to the patient ward. The cost of use of automatic pump for UFH administration was not computed because they were not hospital property and its charge was covered by the cost of pump-specific infusion equipment required. The costs were converted into US dollars considering the mean exchange rate from April to May 2007.
Data were analyzed with PASW Statistics version 18.0 (2009, SPSS Inc., Chicago, IL) and a level of significance of 0.05 was set. Chi-square statistics were used in the comparison of categorical variables and Student t or Mann-Whitney tests were applied to compare continuous variables. Although costs and time of treatment had small skewness deviation, t test and Mann-Whitney results were similar and t test value was provided to compare means. Logistic regression modeling was applied to analyze the association of heparin form and composite clinical outcomes, to take into account potential confounders identified in crude analyses. Sensitivity analyses were performed during June 2010, considering the actual cost of drugs to account for acquisition prices variation. Propensity score for LWMH prescription was computed to adjust for indication bias.
Results
From the 200 patients included, 33 were excluded because they had been treated for arterial thrombosis. Twelve patients received both heparins and were classified in the group of UFH (n ϭ 7) or LMWH (n ϭ 5) according to the first drug prescribed. The change from the first prescribed drug to the other was more frequent in the UFH group (14.0% vs. 4.3% P ϭ 0.044). The characteristics of the groups are similar when excluding the 12 patients that received both heparins ( Only general surgery had crude association with combined endpoint (death, bleeding, or recurrent VTE). Among nine critically ill patients, six were treated with UFH (12%) and three with LMWH (2,6%) (chi-square P ϭ 0.036). The DVT and PE diagnoses were confirmed in 93.0% and in 51.7% of patients, respectively. The median of days in use of heparin was the same in both groups and warfarin was initiated at the first day in 28.1% of 32 patients on the UFH group and in 24.2% of 89 patients on LMWH group treated with oral anticoagulant. aPTT was monitored in 98% of patients receiving UFH and in 56.4% of patients receiving LWMH. Half of the UFH group had aPTT measured less than once a day ( Table 2 in Supplemental Materials found at: doi: 10.1016/j.jval.2011.05.017). Nonstatistically significant differences were observed in the number of bleeding events (10.0% in UFH and 9.4% in LMWH; chi-square P ϭ 1.00), blood transfusion (2.0% and 2.6%; chi-square P ϭ 1.00), and death (8.0% and 3.4%; chi-square P ϭ 0.242). Only one patient in the UFH group evolved to PE. Combined endpoint consisting of recurrent VTE, bleeding, or in-hospital death occurred in 20.0% and 14.5% of patients in the UFH and LMWH groups, respectively (chi-square P ϭ 0.379). In a logistic regression model, adjusted for propensity score to receive UFH and for the hospital ward (clinical or obstetric unit, surgery unit, or intensive care unit), LMWH group members showed no significant risk reduction of combined outcome (odds ratio 0.87; 95% confidence interval 0.32-2.41; P ϭ 0.79).
We calculated the drug cost per day of treatment taking into account the actual price for the institution (Table 3 in Supplemental Materials found at: doi:10.1016/j.jval.2011.05.017). We excluded patients who were treated initially with one form of heparin and then changed to other on the follow-up (12 individuals). Daily mean cost per patient was US$12.63 Ϯ $4.01 for UFH and US$9.87 Ϯ $2.44 for LWMH (t test P Ͻ 0,001). The total cost of short-term heparin treatment considering the mean length of use was US$88.39 and US$69.11, respectively, representing a cost saving of US$19.28 per heparin treatment. The medication itself is the main component of the LMWH group costs (92.88%), whereas it represents only 5.25% of costs in the UFH group ( 
Discussion
This was a pharmacoeconomic analysis of heparin use to treat VTE conducted in a developing country, through cost analysis from a public health perspective. This kind of analysis is justified based on the therapeutic equivalence between initial treatment of DVT and PE with UFH and LMWH [5] . One characteristic that distinguishes our study is the evaluation of a real cohort rather then a hypothetical one, concomitantly including groups of patients receiving different treatments. This reflects the usual care of these patients and makes it possible to estimate the actual costs of treatment in a defined setting.
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Patients included in the study were younger then those of hypothetical cohorts [17, 18] and similar to those of other pharmacoeconomic analyses that collected data from individual patients [14, 19] . Sex is not a risk factor for VTE and is in accordance with the nonsignificant predominance of women in the sample [20] . The 18.6% prevalence of confirmed PE in the studied sample is similar to the 19% in a clinical trial of VTE [12] . In the same trial the major or minor bleeding rates were lower then those recorded in our cohort but they were not different between the treatment groups either.
There was no difference on clinical outcomes between the two groups. This is in accordance with others studies [12, 13] , but clinical trials are not all consistent about equivalence between enoxaparin and UFH. A meta-analysis [21] demonstrated a statistically significant reduction in clinical outcomes with LMWH when combining all trials, but benefit persisted only for reduction of the thrombus size when the 11 studies with adequate concealment of allocation before randomization were considered. Comparison with literature is difficult because the conditions affecting enrolled patients in clinical trials are quite different and the small sample size is a limitation that precludes a definitive conclusion of our study.
We did not expect that LMWH prescription was greater than UFH prescription because the institutional policy during the study period reinforced the use of UFH for VTE treatment based on equal efficacy and lower acquisition costs. The preferred use of UFH in renal failure is recommended in view of the plasmatic accumulation due to delayed elimination and risk of excessive anticoagulant effect [22] . In surgical patients, the preference could be related to the potential for reversion of anticoagulant effect with protamine and the shorter half-life then LMWH in case of bleeding. On the other hand, the preference for using LMWH in face of previous PE is not evidence-based. The crossover from one drug to another was not expected either, but we did not investigate the reasons for it. The greater proportion of infected, critically ill, and diabetic patients in the UFH group suggests they were at higher risk and may be responsible for the statistically nonsignificant increase in death rate in this group. The propensity score was constructed to adjust for these risk factors and was included in the logistic regression model that showed no independent association of heparin group with the composite endpoint. But the nonsignificant relative risk reduction of 17% favoring LMWH may be explained by the small sample size and lack of power.
The total costs of initial treatment for VTE were less expensive with enoxaparin than with UFH, providing an economic advantage of 21.0%. It provided cost savings regardless of the abuse in ordering monitoring laboratory tests when LMWH was prescribed. If we had computed the costs of automatic infusion pump use this economic advantage would be even greater. The economic advantages are in agreement with those found in studies that compared the costs of UFH and LMWH for VTE treatment [14, 15, 16, 18, 23, 24] despite the differences in cost components like home care [14, 23] , outpatient treatment [14] , and the health care providers' perspective [18] . It must be emphasized that the institution is a tertiary university-affiliated hospital that acquires great quantities of the drug. Therefore, it is a favored buyer that can purchase LMWH at prices significantly lower than the average wholesale price. The costs saving associated to LMWH may be explained mainly by the supplies associated with UFH treatment. Besides of the same duration of UFH and LMWH use, computing the costs of hospitalization must implicate in greater economic differences because UFH seems to be mainly indicated for more severely ill patients. It must be noted that total cost, including hospitalization cost was not adjusted for the clinical disadvantages of patients with UFH. The sensitivity analysis was performed computing actual drugs' prices in June 2010. The economic LMWH advantage became even greater as a result. Because of evidence of a drug contaminant associated with greater incidence of adverse reactions UFH had its commercialization stopped [25] . When commercialization restarted, there was a considerable price increase for UFH, inflating costs still further.
Conclusions
Treatment of VTE with enoxaparin provided costs savings in a large teaching hospital located in southern Brazil, from the institutional perspective. Despite differences in the settings where studies of economic evaluation were conducted, the findings agree in regard to the economic advantages of use of LMWH. Implementation of a critical pathway for anticoagulation is desirable to promote rational use of heparins and to save costs.
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